Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The US paid the most for azithromycin in Q2 2026: USD 92.5/KG, up 2.0% from USD 90.7 in Q1. The steady generic-antibiotic demand kept things firm there. Worldwide, the average moved up 2.0%, to USD 80.0/KG from USD 78.4, largely because the erythromycin-derived feedstock costs kept climbing across every region we track. What about H2 2026? We'd expect a global average somewhere in the USD 79.0-86.0/KG range, with the steady respiratory-formulation demand doing most of the work.
Azithromycin is made from erythromycin, itself a fermentation product, through a multi-step process involving hydroxylamine and methyl iodide that converts the macrolide backbone into its more stable, longer-acting azalide form. It's one of the most widely prescribed antibiotics in the world, valued clinically for its short dosing course and broad activity against respiratory and some sexually transmitted infections. As a long-off-patent generic, its demand tracks population respiratory-health needs more than any single innovation cycle. Three things move the price more than anything else: the erythromycin fermentation feedstock costs, the generic-formulation demand from pharmaceutical manufacturers, and how much API capacity the producers in China and India are running. That off-patent status also means pricing here reflects a genuinely competitive generic market rather than the pricing power a single patent holder might exercise, which is part of why the quarter-to-quarter moves track feedstock costs so closely rather than showing the kind of pricing discretion a branded pharmaceutical product might display.
The erythromycin fermentation step deserves a closer look, since it's the foundation everything else in this market is built on. Fermentation-based production is inherently less predictable than straightforward chemical synthesis, since factors like the fermentation broth quality, temperature control, and even the specific microbial strain a facility uses can affect the yield from batch to batch. That variability is part of why this market shows somewhat more quarter-to-quarter movement than a purely synthetic pharmaceutical intermediate would. Producers have invested heavily over the years in tightening that variability through better process controls, though it has never been eliminated entirely, which is part of why this market rewards buyers who work with established, track-record producers over newer entrants offering marginally lower prices.
The short dosing course that makes azithromycin clinically attractive, often just three to five days compared to the longer courses many other antibiotics require, has also made it a particularly convenient choice in outpatient settings and in regions with less developed healthcare infrastructure, which has helped keep global demand broad-based and fairly resilient across both developed and developing markets. Manufacturers who diversify across multiple fermentation sites tend to weather these disruptions better than those relying on a single facility, a lesson several producers took to heart after past supply interruptions rippled through pricing more sharply than expected.
Supply and demand should stay moderately tight through H2 2026, with the erythromycin feedstock costs doing most of the work on pricing. Italy and the US both kept the generic-formulation demand steady through H1, and that's likely to continue. China's large API base should keep the supply ample even as the domestic and export demand both firm.
Buyers should keep an eye on the broader erythromycin fermentation market specifically, since any capacity disruption there, whether from a plant shutdown or a batch-quality issue at a major facility, tends to show up in azithromycin pricing within a quarter.
Buyers should also factor in the modest seasonal demand pattern this market shows, with respiratory-infection rates typically climbing during the colder months and easing back through the warmer stretch of the year, a rhythm that has held fairly consistently across the markets we track. Buyers negotiating longer-term supply agreements should factor that seasonal rhythm into their planning rather than treating each quarter's move as an isolated event. It has held fairly consistently across the four markets we track for as long as we have been following this commodity.
What could push prices higher? An erythromycin fermentation feedstock spike, or a stronger-than-expected seasonal surge in respiratory-infection demand. What could pull them lower? Expanded low-cost Chinese or Indian API capacity outpacing the demand.
| Region | 2026 Price Range (USD/KG) | Outlook |
| Global Average | 79.0 - 86.0 | Steady respiratory-formulation demand and firm feedstock costs support |
| China | 66.5 - 72.2 | Large API base keeps China most affordable |
| India | 73.5 - 79.8 | Established generic-formulation demand |
| Italy | 83.8 - 91.0 | European regulatory-grade demand |
| United States | 91.4 - 99.2 | Steady formulation demand drives premium |
China's azithromycin producers passed through the firmer erythromycin costs this quarter, and the domestic formulation demand held steady. The gain came to 2.0%, USD 66.0/KG to USD 67.3.
Why did the price of Azithromycin change in Q2 2026 in China?
The erythromycin fermentation feedstock costs firmed through the quarter, and the domestic formulation demand held its ground right alongside that.
India climbed 2.1% to USD 74.4/KG, the established generic-formulation demand staying firm through the period.
Why did the price of Azithromycin change in Q2 2026 in India?
The generic-formulation demand stayed firm, and the erythromycin feedstock costs climbed alongside it.
Italy gained 2.0% to USD 84.8/KG, the European regulatory-grade demand continuing to hold steady through the period.
Why did the price of Azithromycin change in Q2 2026 in Italy?
The European regulatory-grade demand held steady, and that alone explains most of the move here.
USD 92.5/KG. That's where the US landed in Q2, up 2.0% from USD 90.7 in Q1. The formulation demand stayed steady, and the feedstock costs climbed just enough to push things higher.
Why did the price of Azithromycin change in Q2 2026 in United States?
The formulation demand didn't move much, honestly. It was the feedstock costs doing most of the work this quarter.
China gained 2.0% to USD 66.0/KG, the demand firming as the year opened.
Why did the price of Azithromycin change in Q1 2026 in China?
The domestic formulation demand firmed as the year opened, and the erythromycin feedstock costs edged higher right alongside it.
India rose 2.0% to USD 72.9/KG, the formulation demand firming with the new year.
Why did the price of Azithromycin change in Q1 2026 in India?
The generic-formulation demand firmed with the new year, and the feedstock costs kept climbing steadily too.
Italy gained 2.0% to USD 83.1/KG, the regulatory-grade demand staying firm through the quarter.
Why did the price of Azithromycin change in Q1 2026 in Italy?
The European regulatory-grade demand stayed firm, and the feedstock costs firmed alongside it.
US azithromycin rose 2.0% to USD 90.7/KG, the formulation demand building through the quarter.
Why did the price of Azithromycin change in Q1 2026 in United States?
The formulation demand built through the quarter, tracking the prescription volumes closely.
The global average climbed steadily across the window, from USD 73.5/KG in Q1 2025 to USD 80.0 by Q2 2026, a net gain of about 8.8%. Every quarter posted a gain here, reflecting the firming erythromycin fermentation feedstock costs and the steady generic-formulation demand across every market we track, with a mild acceleration visible in the most recent two quarters.
| Quarter | Price (USD/KG) | QoQ Change | Direction |
| Q2 2026 | 80.0 | +2.0% | ↑ Rising |
| Q1 2026 | 78.4 | +2.0% | ↑ Rising |
| Q4 2025 | 76.9 | +1.6% | ↑ Rising |
| Q3 2025 | 75.7 | +1.5% | ↑ Rising |
| Q2 2025 | 74.6 | +1.5% | ↑ Rising |
| Q1 2025 | 73.5 | - | - Stable |
| Q3 2026 | In Progress | - | - In Progress |
2025 was a steadily firming year for azithromycin. Starting near USD 73.5/KG in Q1, the global average finished 2025 at USD 76.9, a gain of about 4.6%. The erythromycin fermentation feedstock costs firmed gradually all year, and the generic-formulation demand held dependable throughout, giving the whole year a fairly orderly, predictable shape.
Chinese prices moved from about USD 62.0/KG in Q1 2025 to USD 64.7 by Q4, up roughly 4.4%. The domestic demand held steady all year, and China stayed the most affordable of the four markets throughout.
Indian prices climbed from USD 68.5/KG in Q1 to USD 71.5 by Q4, a 4.4% gain, tracking the steady generic-formulation demand through the year.
Italian prices rose from USD 78.0/KG in Q1 to USD 81.5 by Q4, up 4.5%, as the European regulatory-grade demand stayed firm.
US prices moved from USD 85.0/KG in Q1 to USD 88.9 by Q4, a 4.6% gain, the highest absolute price throughout the four markets on the steady formulation demand.
Expert Market Research: Your Source for Real-Time Azithromycin Price Intelligence
We keep a continuous eye on the azithromycin prices wherever it's produced or consumed at scale, tracing causation through the erythromycin fermentation feedstock economics, the generic-formulation demand, and the API capacity utilization across China and India. Our analysts track the fermentation-supply side particularly closely, given how much batch-to-batch variability can affect this market compared to purely synthetic pharmaceutical intermediates, and we monitor the seasonal respiratory-infection trends that typically shape demand through the colder months. Need pricing data, bespoke market analysis, or procurement advisory? Reach out to our team. We also flag any regulatory or manufacturing-site news that could affect supply before it fully shows up in the pricing data.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
It's one of the most widely prescribed antibiotics in the world, valued clinically for its short dosing course and broad activity against respiratory and some sexually transmitted infections.
In Q2 2026, it averaged USD 67.3/KG in China, USD 74.4/KG in India, USD 84.8/KG in Italy, and USD 92.5/KG in the US, still the priciest market on the steady formulation demand.
The global average climbed from USD 76.9/KG in Q4 2025 to USD 78.4 in Q1 2026, then on to USD 80.0 in Q2, up 4.0% across the half.
The erythromycin fermentation feedstock costs firmed across every region, while the generic-formulation demand held steady to strong across every market tracked.
We're expecting a global average somewhere in the USD 79.0-86.0/KG range, supported by the steady respiratory-formulation demand.
The US carries the firmest premium on the steady formulation demand. Italy sits close behind on the European regulatory-grade demand. China prices lowest on its large API production base.
The erythromycin fermentation feedstock costs matter most, followed by the generic-formulation demand and the API capacity utilization.
China and India together account for the large majority of global API production, while Italy hosts established regulatory-grade production for European formulators.
Monthly, though our analysts flag any material shift in feedstock or logistics conditions between scheduled updates. Need something more current? Our team is available directly.
The quarterly trends and forecasts help time formulation-linked purchasing around the erythromycin feedstock cycles. Tracking the API capacity utilization across China and India can help buyers anticipate the supply-driven price moves. Building that habit into a quarterly procurement review tends to pay off more than reacting to price moves after they have already happened.
One Year Subscription
One Year Subscription
USD 799
USD 699
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.